NUTM1 and metastatic neoplasm: Patients with non-BRD4-NUTM1 fusions (BRD3- or NSD3-NUTM1, median overall survival, 36.5 months) have significantly better survival than those with BRD4-NUTM1 fusions (median overall survival, 10 months), independently of metastatic disease extent at presentation [98].